EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Screening for pre‐eclampsia using pregnancy‐associated plasma protein‐A or placental growth factor measurements in blood samples collected at 8–14 weeks' gestation

L Rode iD, A Wright, D Wright, M Overgaard, L Sperling, P Sandager, P Nørgaard, F S Jørgensen, H Zingenberg, I Riishede iD, A Tabor, C K Ekelund und 1 weitere

Ultrasound in Obstetrics & Gynecology · 2025

DOI: 10.1002/uog.29204 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ultrasound in Obstetrics & Gynecology, 2025. Verfasst von L Rode und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Pregnancy-Associated Plasma Protein-A, Placenta Growth Factor, Pre-Eclampsia, Prenatal Diagnosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research Fund between Copenhagen University Hospital Rigshospitalet and Odense University Hospital, Jascha Fonden, The Research Fund of the Capital Region of Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the value of pregnancy‐associated plasma protein‐A (PAPP‐A) in screening for preterm pre‐eclampsia (PE) (delivery < 37 weeks' gestation) measured in maternal blood samples collected before 11 weeks, and to compare the screening performance of PAPP‐A with that of placental growth factor (PlGF) from blood samples collected at 8–14 weeks.

Methods

This study analyzed data from women who participated in the PRESIDE (Pre‐eclampsia Screening in Denmark) study, a prospective, non‐interventional multicenter study investigating the predictive performance of the Fetal Medicine Foundation first‐trimester screening algorithm for PE in a Danish population. As part of combined first‐trimester screening, a routine blood sample was collected at 8–14 weeks' gestation and PAPP‐A was measured. Excess serum was stored at −80°C and analyzed for PlGF in batches after delivery. Most women in the PRESIDE study had an extra blood sample collected at the time of the first‐trimester scan at 11–14 weeks, which was also analyzed for PlGF and PAPP‐A in batches after all the participants had delivered. Screening performance was assessed in terms of the detection rate at a 10% screen‐positive rate (SPR) for a combination of PAPP‐A or PlGF with maternal factors alone and for a combination of each of these biomarkers with maternal factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA‐PI).

Results

The study population comprised 8386 women who had a routine combined first‐trimester aneuploidy screening blood sample collected at 8–14 weeks' gestation. In pregnancies that developed preterm PE, the median PAPP‐A multiples of the median from routine blood samples were 0.78 (95% CI, 0.67–0.90) before 10 weeks, 0.80 (95% CI, 0.58–1.10) at 10 weeks and 0.64 (95% CI, 0.53–0.78) at 11–14 weeks. In women with samples collected before 10 weeks, there was no significant improvement in the detection rate of preterm PE when PAPP‐A or PlGF was combined with maternal factors alone or when combined with maternal factors, MAP and UtA‐PI. In routine samples collected at or after 10 weeks, PAPP‐A only increased the detection rate of preterm PE slightly. However, PlGF in samples collected at or after 10 weeks increased the detection rate from 31.3% (95% CI, 16.1–50.0%) to 56.3% (95% CI, 37.7–73.6%) at a 10% SPR, i.e. an increase in the detection rate of 25.0% (95% CI, 4.3–44.4%), when combined with maternal factors alone. When PlGF collected from the PRESIDE sample at 11–14 weeks was combined with maternal factors, MAP and UtA‐PI, there was an increase in the detection rate from 50.9% (95% CI, 37.1–64.6%) to 67.3% (95% CI, 53.3–79.3%), i.e. an increase of 16.4% (95% CI, 5.6–29.0%) at a 10% SPR.

Conclusions

PAPP‐A has limited value in first‐trimester screening for PE, whereas PlGF adds significantly to the detection rate of preterm PE at 10–14 weeks' gestation. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy-Associated Plasma Protein-APlacenta Growth FactorPre-EclampsiaPrenatal DiagnosisHumansFemalePregnancyPregnancy Trimester, FirstProspective StudiesAdultBiomarkersGestational AgeDenmarkPredictive Value of Tests

Stichwörter der Autor:innen

Fetal Medicine Foundationcompeting‐risks modelfirst trimesterplacental growth factorpregnancy‐associated plasma protein‐apre‐eclampsiascreening

Substanzen

Pregnancy-Associated Plasma Protein-APlacenta Growth FactorBiomarkersPGF protein, human

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Center for Fetal Medicine and Pregnancy, Department of Gynecology, Fertility, and Obstetrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Institute of Health Research, University of Exeter, Exeter, UK.
  • Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Fetal Medicine Unit, Department of Obstetrics and Gynecology, Odense University Hospital, Odense, Denmark.

ORCID-Profile: L Rode, I Riishede

Förderung

  • The Research Fund between Copenhagen University Hospital Rigshospitalet and Odense University Hospital
  • Jascha Fonden
  • The Research Fund of the Capital Region of Denmark
  • The Research Fund of Copenhagen University Hospital Rigshospitalet
  • Fonden til Lægevidenskabens Fremme
  • Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat

Zitieren

APA

Rode, L., Wright, A., Wright, D., Overgaard, M., Sperling, L., Sandager, P., Nørgaard, P., Jørgensen, F. S., Zingenberg, H., Riishede, I., Tabor, A., Ekelund, C. K., & PRESIDE Study Group (2025). Screening for pre‐eclampsia using pregnancy‐associated plasma protein‐A or placental growth factor measurements in blood samples collected at 8–14 weeks' gestation. Ultrasound in Obstetrics & Gynecology. https://doi.org/10.1002/uog.29204

Vancouver

Rode L, Wright A, Wright D, Overgaard M, Sperling L, Sandager P, et al. Screening for pre‐eclampsia using pregnancy‐associated plasma protein‐A or placental growth factor measurements in blood samples collected at 8–14 weeks' gestation. Ultrasound in Obstetrics & Gynecology. 2025. doi:10.1002/uog.29204

BibTeX
@article{Rode2025,
  author = {Rode, L and Wright, A and Wright, D and Overgaard, M and Sperling, L and Sandager, P and Nørgaard, P and Jørgensen, F S and Zingenberg, H and Riishede, I and Tabor, A and Ekelund, C K and PRESIDE Study Group, PRESIDE Study Group},
  title = {Screening for pre‐eclampsia using pregnancy‐associated plasma protein‐A or placental growth factor measurements in blood samples collected at 8–14 weeks' gestation},
  journal = {Ultrasound in Obstetrics & Gynecology},
  year = {2025},
  doi = {10.1002/uog.29204}
}
Kostenlos starten →